Genmab revenue and financials
Secondary listing. The primary listing is Genmab · Nasdaq Copenhagen (DKK)
$37.80Change from previous close: −1.77%Absolute change: −$0.68
In the fiscal year ended December 2025, Genmab reported revenue of kr 3.72B (+19.19% year over year). Net income was kr 963M, a net margin of 25.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +19.19%
- 2025 vs 2024
- Net income growth
- −87.72%
- 2025 vs 2024
- Net margin
- 25.9%
- 2024: 251.3%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Total assets | 12,873 | 45,811 | 5,232 | 15,144 | 8,461 | — |
| Current assets | 2,885 | 3,900 | 4,912 | 13,961 | 7,433 | — |
| Cash and equivalents | 1,715 | 1,380 | 2,204 | 3,552 | 533 | 1,348 |
| Short-term investments | 0.0 | 1,574 | 1,967 | — | — | — |
| Receivables | 1,152 | 937 | 733 | — | — | — |
| Inventory | 18.0 | 9.0 | 8.0 | — | — | — |
| Net property, plant and equipment | 280 | 265 | 244 | — | — | — |
| Goodwill | 355 | 355 | 0.0 | — | — | — |
| Other intangible assets | 9,123 | 1,728 | 15.0 | — | — | — |
| Long-term investments | 37.0 | 32.0 | 20.0 | — | — | — |
| Current liabilities | 1,427 | 744 | 368 | 938 | 444 | — |
| Long-term debt | 5,274 | 0.0 | — | — | — | — |
| Total debt | 5,426 | 144 | 114 | — | — | — |
| Total liabilities | 7,026 | 1,277 | 545 | 1,096 | 447 | — |
| Total equity (incl. minority) | 5,847 | 5,137 | 4,687 | — | — | — |
| Retained earnings | 4,098 | 3,392 | 2,737 | — | — | — |